Fundraising FoxValitor
Berkeley, US · Founded 2018 · Delaware corporation · 8 known investors
Find your way into Valitor
Sign up to see every warm intro you have to Valitor
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Valitor team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.
Founders & leadership
Board
Investors · 8
How we know: Angel Physicians Fund's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: First Spark Ventures, Llc's portfolio page · funding news · globenewswire.com · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$38.2M disclosed across 3 rounds · 2018–2022
- $28MSeries BOct 2022 · 4 sources
Morningside (lead), Berkeley Catalyst Fund, ExSight Ventures, First Spark Ventures, Pandect Bioventures
Source ↗
▶$8.4MraisedJan 2022 · 8 investors · OtherRule 506(b)
- Walter MoosDirector
- Anthony AiudiDirector
- Kevin E. HealyDirector
- Gail MaderisDirector
- Manish KothariDirector
- Wesley M. JacksonExecutive Officer, Director
- Offering amount
- $32.7M
- Amount sold
- $8.4M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$1.7MraisedSep 2018 · 6 investors · OtherRule 506(b)
- Carole H BellisExecutive Officer
- Drew LanzaDirector
- Kevin E HealyDirector
- Walter MoosDirector
- Jackson M WesleyExecutive Officer, Director
- Offering amount
- $2.8M
- Amount sold
- $1.7M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Valitor went on to found or lead other companies.
Related companies · 3
Companies working in the same space as Valitor.
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $298.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $318.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $284.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $310.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $311.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Valitor do?
- Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.
- Who are Valitor's investors?
- Valitor's investors include Angel Physicians Fund, Berkeley Catalyst, ExSight Ventures, First Spark Ventures, Llc, Pandect Bioventures, Taihill Venture.
- How much funding has Valitor raised?
- Valitor has disclosed $38.2M raised across 3 rounds.
- Where is Valitor headquartered?
- Valitor is headquartered in Berkeley, US.